



אפריל 2019

פייזר פי אף אי פרמצבטיקה ישראל בע"מ  
רח' שנקר 9, ת.ד. 12133  
הרצליה פיתוח, ישראל 46725  
טל: 972-9-9700500 פקס: 972-9-9700501

רופא/ה, רוקח/ת נכבד/ה,

**Zithromax I.V.** : (במתכונת עלון לרופא) :  
המרכיב הפעיל:

Azithromycin (as dihydrate) 500mg/vial

**Indicated for:**

Treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

להלן העדכונים העיקריים בעלון לצרכן (במתכונת עלון לרופא):

.....

## 7 DRUG INTERACTIONS

.....

### 7.3 Potential Drug-Drug Interaction with Macrolides

Interactions with ~~the following drugs listed below~~ digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. ~~however, No~~ specific drug interaction studies have been performed to evaluate potential drug-drug interaction. However, drug interactions have been observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised.

.....

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

**Teratogenic Effects. Pregnancy Category B:**

#### Risk Summary

Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 4, 2, and 2 times, respectively, an adult human daily dose of 500 mg based on body surface area. Decreased viability and delayed development were observed in the offspring of pregnant rats administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 4 times an adult human daily dose of 500 mg based on body surface area (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

#### Data

##### Human Data

Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.

### Animal Data

Reproductive and ~~development~~ developmental toxicology studies have not been conducted using IV administration of azithromycin to animals. ~~Reproduction studies~~ Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 4 (rats) and 2 (mice) times an adult human daily dose of 500 mg. In rabbits administered azithromycin at oral doses of 10, 20, and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2 times an adult human daily dose of 500 mg based on body surface area.

In a pre- and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 or 200 mg/kg/day. Maternal toxicity (reduced food consumption and body weight gain; increased stress at parturition) was observed at the higher dose. Effects in the offspring were noted at 200 mg/kg/day during the postnatal development period (decreased viability, delayed developmental landmarks). These effects were not observed in a pre- and postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until weaning.

## **8.2 Lactation**

### Risk Summary

Azithromycin is present in human milk (see Data). Non-serious adverse reactions have been ~~performed in rats and mice using oral~~ reported in breastfed infants after maternal administration ~~at doses up to moderately maternally toxic dose~~ of azithromycin (see *Clinical Considerations*). There are no available data on the effects of azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZITHROMAX and any potential adverse effects on the breastfed infant from ZITHROMAX or from the underlying maternal condition.

### Clinical Considerations

**Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.**

### Data

~~Azithromycin breastmilk concentrations (i.e., 200 mg/kg/day). These daily doses in rats and mice based on body surface area, are estimated to be 4 and 2 times, respectively, an adult daily dose of 500 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and were measured in 20 women after receiving a single 2 g oral dose of azithromycin during labor. Breastmilk samples collected on days 3 and 6 postpartum as well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed, as 2 and 4 weeks postpartum revealed the presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study, a single dose of azithromycin 500 mg was administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.~~

## **8.2 Nursing Mothers**

~~Azithromycin has been reported to be excreted in human breast milk in small amounts. Caution should be exercised when azithromycin is administered to a nursing woman.~~

.....

השינויים המודגשים ברקע צהוב מהווים החמרה. כמו כן, בוצעו שינויים נוספים הכוללים תוספת מידע, השמטת מידע ועדכוני נוסח שאינם מהווים החמרה. בהודעה זו מצוינים רק העדכונים העיקריים. קיימים עדכונים נוספים.

העלונים המעודכנים נשלחו למשרד הבריאות לצורך פרסומם במאגר התרופות שבאתר משרד הבריאות:

<https://www.old.health.gov.il/units/pharmacy/trufot/index.asp?safa=h>

לחילופין, לקבלת עלונים מלאים מודפסים ניתן לפנות לחברת פייזר פי אף אי פרמצבטיקה ישראל בע"מ

שנקר 9, ת.ד. 12133

הרצליה פיתוח, 46725.

בברכה,

עשת אושרית

רוקחת ממונה

